Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc. > for the newbies the voucher has a an estimated value

<< Previous

Bullboard Posts

Next >>

Comment by stockbuphoonon Jun 28, 2021 11:22pm

58 Views

Post# 33464533

RE:RE:for the newbies the voucher has a an estimated value

Very good call. It's hard for money alone to add anything to share price without a potential speculative blockbuster. They either never had it or they are currently burying it. I think it is the latter from management's bizarre press releases. And to say that they need to announce everything immediately when known is a change in most management philosophy as most companies will wait until the end of sturdy to report the full scope of indication results as they are studying many organs. It's pretty clear that there are games being played in another ugly way trying to drive this thing down slowly in a ugly grave on public markets. SALP owns the IP.

stockman6767 wrote: Newcamo, you posted (many times):
"

for the newbies the voucher has a an estimated value

tHANKS to the FDA green light yesterday, the priority voucher will be sold on market, its value is of 80M$ to 120M$ u.s. Lets go with 100M$....lmnl gets 70%, +5M$ + 17M$, all u.s.$....so lmnl gets 70M+17M+5M= 92M$ u.s.... about 100M$ canadian... market cap on NR was about ...100M$ as well so i see major push next days.

at least 10$+ next trading days (market cap is extremely low)"

However, this makes no sense to projext high share price based on the FDA approval! Here is why.

NORMALLY WHEN YOU GET AN FDA APPROVAL, YOU ARE NOW GUARANTEED A STEADY STREAM OF REVENUS IN THE FUTURE. UNFORUNATELY FOR LMNL, KEDRION WIL BE THE BENEFICIARY OF THIS FUTURE REVENUE STREAM. ALL LMNL WILL GET IS THE $5 M OPTION PAYMENT AND A ONE TIME LUMP SUM OF ABOUT $70 M FOR THE VOUCHER! NOTHING FROM THIS DOWN THE ROAD. THUS WITH 29 MILLION OUTSTANDING SHARES ALL THIS IS WORTH PER SHARE IS $70M + $5M / 29 M = $2.59 .PER SHARE OVER CURRENT PRICE AND THEN DRIFT DOWNWARD FROM THERE AS THERE IS NOTHING HERE THAT SPEAKS TO FUTURE REVENUE. FOR THAT THEY WILL HAVE TO WAIT MANY YEARS, SPEND MORE MONEY ON CLINICAL TRIALS FOR A SHOT AT A POSSIBLE REVNUE STREAM WAY DOWN THE ROAD IF EVERYTHING GOES RIGHT. THIS IS NOT WHAT CURRENT INVESTORS WANT, DEAD MONEY FOR MANY YEARS.
SO I PREDICT THE SHARES WILL GO TO SOMETHING OVER $4.15 + $2.59 -= $6.74 (AND PERHAPS OVERSHOOT THAT FOR A BRIEF EXUBERANCE IF THAT HAS NOT ALREADY HAPPENED AFTER MARKET) AND THEN DRIFT DOWN TO THE RECENT TARGET OF $4.50 OR BELOW!